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their  high  HbS  concentration,  and    HbS  polymers  may  be  formed  under  normal  oxygen 
pressure. Pathophysiological studies have shown that the dense, dehydrated red cells may 
play a central role in acute and chronic clinical manifestations of sickle cell disease, in which 
intravascular sickling in capillaries and small vessels leads to vaso
blood flow in a variety of organs and tissue. The persistent membrane damage associated with 
HbS polymerization also favors the generation of  distorted rigid cells and further contributes 
to  vaso-occlusive  crisis  (VOCs)  and  cell  destruction  in  the  peripheral  circulation.  These 
damaged,  dense  sickle  red  cells  also  show  a  loss  of  phospholipid  asymmetr
externalization  of  phosphatidylserine  (PS),  which  is  believed  to  play  a  significant  role  in 
promoting  macrophage  recognition  with  removal  of  erythrocytes  (erythrophagocytosis). 
Vaso-occlusive events in the microcirculation result from a complex scen
interactions  between  different  cell  types,  including  dense,  dehydrated  sickle  cells, 
reticulocytes, abnormally activated endothelial cells, leukocytes, platelets and plasma factors 
such as cytokine and oxidized pro
currently the only drug approved for chronic administration in adult patients with sickle cell 
disease to prevent acute painful crises and reduce the incidence of transfusion and acute chest 
crises. Here, we will focus on c
treatment of sickle cell disease, including:
a) agents which reduce or prevent sickle cell dehydration
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A homozygous mutation in the gene for  globin, a subunit of adult hemoglobin A 
(HbA), is the proximate cause of sickle cell disease (SCD). Sickle hemoglobin (HbS) shows 
peculiar  biochemical  properties,  which  lead  to  polymerizing  when  deoxygenated.    HbS 
polymerization is associated with a reduction in cell ion and water content (cell dehydration), 
increased red cell density which further accelerate HbS polymerization. Dense, dehydrated 
erythrocytes are likely to undergo instant polymerization in conditions of mild hypoxia due to 
their  high  HbS  concentration,  and    HbS  polymers  may  be  formed  under  normal  oxygen 
Pathophysiological studies have shown that the dense, dehydrated red cells may 
d chronic clinical manifestations of sickle cell disease, in which 
intravascular sickling in capillaries and small vessels leads to vaso-occlusion and impaired 
blood flow in a variety of organs and tissue. The persistent membrane damage associated with 
polymerization also favors the generation of  distorted rigid cells and further contributes 
occlusive  crisis  (VOCs)  and  cell  destruction  in  the  peripheral  circulation.  These 
damaged,  dense  sickle  red  cells  also  show  a  loss  of  phospholipid  asymmetr
externalization  of  phosphatidylserine  (PS),  which  is  believed  to  play  a  significant  role  in 
promoting  macrophage  recognition  with  removal  of  erythrocytes  (erythrophagocytosis). 
occlusive events in the microcirculation result from a complex scen
interactions  between  different  cell  types,  including  dense,  dehydrated  sickle  cells, 
reticulocytes, abnormally activated endothelial cells, leukocytes, platelets and plasma factors 
such as cytokine and oxidized pro-inflammatory lipids. Hydroxycarbamide (hydroxyurea) is 
currently the only drug approved for chronic administration in adult patients with sickle cell 
disease to prevent acute painful crises and reduce the incidence of transfusion and acute chest 
Here, we will focus on consolidated and experimental therapeutic strategies for the 
treatment of sickle cell disease, including:
agents which reduce or prevent sickle cell dehydration
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b) agents which reduce sickle cell-endothelial adhesive events
c) nitric oxide (NO) or NO-related compounds
d) anti-oxidant agents
Correction of  the abnormalities ranging from membrane cation transport pathways to red 
cell-endothelial adhesive events, might constitute new pharmacological targets for treating 
sickle cell disease.
Introduction: A homozygous mutation in the gene 
for   globin,  a  subunit  of  adult  hemoglobin  A 
(HbA), is the proximate cause of sickle cell disease 
(SCD).  Sickle  hemoglobin  (HbS)  shows  peculiar 
biochemical properties, which lead to polymerizing 
when deoxygenated. Studies of the kinetics of HbS 
polymerization  following  deoxygenation  have 
shown it to be a high order exponential function of 
haemoglobin  concentration,  thus  highlighting  a 
crucial  role  for  cellular  HbS  concentration  in 
sickling
1,2.  HbS polymerization is associated with a 
reduction  in  cell  ion  and  water  content  (cell 
dehydration),  increased  red  cell  density  which 
further  accelerate  HbS  polymerization
1-3.  Dense,
dehydrated  erythrocytes  are  likely  to  undergo 
instant  polymerization  in  conditions  of  mild 
hypoxia due to their high HbS concentration, and  
HbS polymers may be formed under normal oxygen 
pressure.
Pathophysiological studies have shown that the 
dense, dehydrated red cells may play a central role 
in  acute  and  chronic  clinical  manifestations  of 
sickle cell disease, in which intravascular sickling 
in  capillaries  and  small  vessels  leads  to  vaso-
occlusion and impaired blood flow in a variety of 
organs  and  tissues
2,4.  The  persistent  membrane 
damage  associated  with  HbS  polymerization  also 
favors  the  generation  of
5 distorted  rigid cells  and 
further contributes to   vaso-occlusive crisis (VOCs) 
and  cell  destruction  in  the  peripheral  circulation. 
These damaged, dense sickle red cells also show a 
loss  of  phospholipid  asymmetry  with 
externalization of phosphatidylserine (PS), which is 
believed  to  play  a  significant  role  in  promoting 
macrophage  recognition  with  removal  of 
erythrocytes  (erythrophagocytosis),  cell  apoptosis 
and  activation  of  coagulation.  Although  the 
percentage of dense erythrocytes does not predict 
the  severity  of  the  disease,  it  has  been  shown  to 
increase  prior  to  or  during  the  first  phase  of  the 
painful crisis and to decrease thereafter
4,6,7. Vaso-
occlusive events in the microcirculation result from 
a  complex  scenario  involving  the  interactions 
between  different  cell  types,  including  dense, 
dehydrated  sickle  cells,  reticulocytes,  abnormally 
activated endothelial cells, leukocytes, platelets and 
plasma  factors  such  as  cytokines
8,9 and  oxidized 
pro-inflammatory lipids
6,10,11.
Hydroxycarbamide  (hydroxyurea)  is  currently 
the only drug approved for chronic administration 
in adult patients with sickle cell disease to prevent 
acute  painful  crises  and  reduce  the  incidence  of 
transfusion and acute chest crises
12. Long-term use 
of  hydroxycarbamide  has  been  demonstrated  to 
produce  dramatic  reductions  in  mortality  and 
morbidity  in  patients  with  sickle  cell  disease
13. 
Clinical use of hydroxycarbamide in pediatric and 
adult patients with sickle cell disease is discussed in 
the  next  chapter  on  clinical  management  (13.2). 
Decitabine has also been shown to be a promising 
agent  for  the  modulation  on  Hb  F  in  sickle  cell 
disease
14.  We  will  focus  here  on  therapeutic 
strategies  currently  being  considered  for  the 
treatment of sickle cell disease, which are not based 
on Hb F modulation. They include:
a) Use of agents which reduce or prevent sickle 
cell dehydration
b) Use  of  agents  which  reduce  sickle  cell-
endothelial adhesive events
c) Use  of  nitric  oxide  (NO)  or  NO-related 
compounds
d) Use of antioxidant agents
a) Prevention of sickle red cell dehydration: One 
of  the  distinguishing  characteristics  of  sickle  cell 
disease  is  the  presence  of  dense  erythrocytes, 
formed as a result of cell dehydration and loss of 
potassium  (K
+).  These  dense  red  cells  generally 
have  a  lower  HbF  content  and  include  both 
reticulocytes  and  red  cells
15.  Usually,  the  dense 
fraction  of  erythrocytes  has  a  high  percentage  of 
irreversible sickle cells (ISCs), cells that maintain 
their sickle shape even when fully oxygenated. An 
inverse correlation has been demonstrated between 
percentage  of  ICSs  and  erythrocyte  survival.  In 
vitro and in vivo studies in animal models for sickle 
cell  disease  have  suggested  a  crucial  role  of 
dehydrated  red  cells in  the  pathogenesis  of  vaso-
occlusive events; in fact, the dense, dehydrated red 
cells  might  be  easily  trapped  in  post  capillary 
venules, promoting micro-vascular obstruction
16. 
Thus,  prevention  of  red  cell  dehydration 
represents  an  exciting  possible  new  therapeutic Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
strategy.  Studies  on  membrane  permeability  in 
sickle  cell  disease  have  shown  abnormalities  in 
different  specialized  membrane-embedded 
transporters  that  carry  cations,  anions  and  water 
across  the  erythrocyte  membrane.  In the  last  two 
decades, studies on the nature and properties of the 
pathways  mediating  K
+ loss  in  sickle  cell 
erythrocytes  have led  to  the  development  of  new 
therapeutic tools to block K
+ loss and dehydration. 
The  major  pathways  for  K
+ loss  during  sickle 
cell  dehydration  events  are  the  Ca
2+-activated  K
+
channel,  known  as  Gardos  channel,  operating  in 
parallel  with  the  conductive  Cl
- pathway  and  the 
electroneutral K-Cl cotransport (Figure 1)
17-22. 
Ca
2+-activated  K
+ channel  (Gardos  channel, 
KCNN4):  Sickle  red  cells  are  characterized  by 
increased amounts of calcium, which is functionally 
and  physically  sequestered  into  intracellular 
vesicles, but maintained in normal concentration in 
the steady state. The cyclic deoxygenation and HbS 
polymerization  that  occurs  in  sickle red  cells  has 
been  shown  to  produce  transient  increase  in  free 
intracellular calcium, which is responsible for large 
K
+ loss  with  associated  Cl- and  water  loss.  This 
effect is due to activation of a specific Ca-gated K
+ 
channel that was first described by Gardos
23. The 
imidazole  antimycotic  clotrimazole  (CLT)  has  
shown  to  be  a  specific  inhibitor  of  the  Gardos 
channel  and  to  prevent  sickle  cell  dehydration  in 
vitro
18. In a transgenic mouse model of sickle cell 
disease, oral administration of CLT was reported to 
specifically block the Gardos channel, increase the 
red  cell  K
+ content  and    reduce  red  cell 
dehydration
24. The compound was further tested in 
normal humans (AA) and in sickle cell volunteers 
(SS), and was shown to be a powerful and effective 
inhibitor  of  the  erythroid  Gardos  channel  and  of 
sickle red cell dehydration
25,26.  Further studies led 
to the development of a novel class of compounds 
based  on  the  back-bone  structure  of  CLT,  which 
have  conserved  Gardos  channel  inhibitory power, 
but are devoid of the imidazole moiety of CLT, and 
thus of cytochrome P450 inhibitory effects
27. One 
of these compounds (ICA-17043) has been shown 
to  have  10-fold  greater  potency  than  CLT  in 
blocking the Gardos channel in vitro and in vivo to 
specifically inhibit Gardos channel and prevent K
+
loss and red cell dehydration
28. Phase I studies in 
normal human subjects and in sickle cell patients, 
showed significant blockade of the Gardos channel, 
in absence of any significant side-effects
29. A phase 
II  study  showed  that  ICA-17043  reduced 
haemolysis and the percentage of dense cells, with a 
significant amelioration of anaemia in patients with 
sickle cell disease
30. However, a Phase III clinical 
trial showed no effect of ICA-17043 on the rate of 
painful events in SCD patients, most likely related 
with  some  effects  on  blood viscosity of red  cells 
displaying  an  increase  survival.  No  other  studies 
have been planned with this molecule.
Another  therapeutic  agent,  which  has  been 
recently  shown  to  modulate  the  Gardos  channel 
activity, is L-Arginine. Patients with SCD show a 
state of relative depletion of arginine, which is part 
of  the  nitric  oxide  pathway.  L-Arginine 
supplementation  of  transgenic  sickle  cell  mice 
resulted in inhibition of erythrocyte Gardos channel 
activity and amelioration of red cell dehydration
16. 
A  phase  II  study  to  test  the  effect  of  arginine 
supplementation  have  shown  no  major  effects  on 
Gardos channel function and erythrocyte hydration 
in patients with sickle cell disease
31,32.
K-Cl cotransport (KCC1/3/4): Several forms of K-
Cl  cotransport have  been  described  in  various 
human and mouse tissues. KCC2 expression seems 
to be limited to brain cells, while human and mouse 
erythrocytes  seem  to  possess  KCC1,  KCC3  and 
KCC4 isoforms in different and still undetermined 
ratio.  The  K-Cl  cotransport  mediates  red  cell 
dehydration  in  SCD.  Studies on  K-Cl  cotransport 
function  have  identified  different  triggers  of 
activation, such as cell swelling, cell acidification, 
reduced cell magnesium (Mg
2+) content, membrane 
oxidative  damage  and  urea.  Franco  et  al.
22    have 
also shown that K-Cl cotransport mainly contributes 
to  dehydration  of  sickle  reticulocytes  and  that 
deoxygenation of sickle red cells also stimulates K-
Cl  cotransport  in  isotonic  solutions  at  pH  7.4
(Figure 1). The relative contribution of the Gardos 
channel  and  of  the  K-Cl  cotransport  pathway  in 
generating  dehydrated, dense  sickle  red  cells  is  a 
complex and still unresolved issue. 
K-Cl  cotransport activity  is  modulated  by  red 
cell Mg content and low Mg
2+ levels are associated 
with abnormal activation of K-Cl cotransport. Some 
small studies have reported a reduction in red cell 
Mg
2+ content  in  SCD  patients.  Thus,  oral  Mg 
supplementation with the aim of increasing red cell 
Mg
2+ levels and inhibiting K-Cl cotransport activity 
may  represent  a  possible  therapeutic  strategy  for 
ameliorating SCD red cell dehydration
16,17. Dietary 
magnesium  supple-mentation  in  transgenic  sickle 
cell  mice  has  demonstrated  that  increasing 
erythrocyte  Mg
2+ content  can  ameliorate  red  cell 
dehydration.  Two  uncontrolled  trials  of  oral 
supplementation  with  Mg  pidolate  have  been 
carried  out  in  sickle  cell  patients,  showing  a 
reduction in K-Cl cotransport activity, an increase Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure  1. Schematic  diagram  of  the  ion  transport  pathways  involved  in  sickle  cell  dehydration  and  action  sites  of  potential 
therapeutic blockers: Ca
2+activated K
+ channel (Gardos channel, KCNN4): Clotrimazole (CLT) and ICA-17043; K-Cl cotransport 
(KCC1/3/4):  Magnesium  (Mg)  Pidolate;  Deoxygenation-induced  pathway:  Dipyridamole;  Anion  conductive  pathway: NS3623. 
Deoxygenation induces Hb S polymerization and sickling, with associated increased membrane permeability and abnormal function
of different ion transport pathways, resulting in K
+, Cl
- and water loss and red cell dehydration (modified from De Franceschi L et al. 
Haematologica 89: 348, 2004). 
in red cell K
+ and Mg
2+ content, an improvement in 
red cell dehydration and a reduction in the number 
of  painful  events
17,33.  A  double-blind,  placebo 
controlled  crossover  study  with  Mg  pidolate 
supplementation in children with sickle cell disease 
did not demonstrate any significant changes in the 
haematological  parameters  studied;  however,  the 
Mg-pidolate dosage used was markedly lower than 
that proposed in the previous studies. In a phase I 
study,  the  therapeutic  association  of  Mg-pidolate 
with  hydroxyurea  have been evaluated in patients 
with HbSC disease, showing a significant reduction 
in  the  activity  of  the  K-Cl  cotransport  after  3 
months of supplementation
34. 
Recently, it  has been reported that  infusion of 
Mg sulfate reduces the length of stay of sickle cell 
patients hospitalized during vaso-occlusive crises
16. 
Cl
- permeability  pathway: Studies  on  the 
conductive  Cl- pathway  indicate  that  for  red  cell 
dehydration  the  movement  of  K
+      must  be 
accompanied  by  that  of  chloride  (or  other 
monovalent  anions)  to  maintain  electroneutrality 
(Figure 1). Elegant sets of studies demonstrate that 
movement  of  K
+ and  dehydration  via  the  Gardos 
channel  can  be  blocked  if  the  Cl
- conductive 
pathway  is  inhibited.  A  specific  inhibitor  of  Cl-
conductance  has  been  recently  developed 
(NS3623).  NS3623  has  been  tested  in  transgenic 
sickle cell mice and was found to reduce in vivo 
sickle cell dehydration, with a mild echinocytosis at 
the highest doses. Unfortunately, NS3623 was not 
further  developed  for  clinical  use  because  of 
undesirable  side  effects  observed  in  human 
subjects
16,19.
b) Anti-adherence therapy in sickle cell disease:
Vaso-occlusive  episodes  are  central  events  in  the 
pathophysiology of sickle cell disease, causing the 
clinical  manifestations  and  leading  to  acute  and 
chronic  organ  damage.  The  abnormal  adhesive 
interactions  between  erythrocyte,  reticulocytes, 
endothelial cells, platelets or soluble mediators may Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
represent  a  possible  new  therapeutic  target.  In 
addition,  SCD  patients  showed  abnormally 
activated circulating endothelial cells that increase 
during  acute  vaso-occlusive  crisis  suggesting  the 
presence  of  chronic  vascular  endothelial  damage 
further  worsening  during  acute  events
4,35-37.  The 
end-point of anti-adherence therapy is to interfere 
with  the  initialization  and/or  amplification  of 
adhesive  events.  Although  anti-adherence  therapy 
has  been  mainly  studied  during  acute  painful 
events, its mechanisms of action are only partially 
known.
4,6,38-40
In SCD, the anti-adherence therapeutic strategies 
(Figure 2) can be divided into: 
i. Molecules interfering with chemical-physical 
processes  during  erythrocyte-endothelial 
adhesion events
ii. Molecules  interfering  with  sickle  cell-
endothelial adhesive mechanisms
iii.Molecules  modulating  inflammatory 
pathways involved in  sickle cell-endothelial 
adhesion
iv. The heme-oxygenase-1 (HO-1) connection
Molecules  interfering  with  chemical-physical 
processes during erythrocyte-endothelial adhesion 
events: Non-ionic surfactant block copolymer such 
as  RheothRx  (Poloxamer  188)  lowering  viscosity 
and frictional forces improves microvascular blood 
flow.  RheothRx  has  been  shown  to  block 
hydrophobic  adhesive  interactions  (cell-cell,  cell-
protein  or  protein-protein  interaction)  in  blood, 
resulting  in  reduction  of  erythrocyte  aggregation 
and  red  cell  adherence  to  vascular  endothelium, 
with a hypothetical improvement in microvascular 
flow
41.  Phase  II  studies  have  shown  a  limited 
favorable  effect in  treatment  of acute pain  crises, 
when associated with hydroxyurea (HU) in sickle 
cell  children.  However,  no  further  clinical 
development studies are planned for this compound.
Molecules interfering with sickle cell-endothelial 
adhesive mechanisms: Recent studies on the sickle 
cell-endothelium  adhesive  mechanism  have 
identified  different  interactions  which  may  have 
particular  therapeutic  relevance:  a)  the  integrin  
a4b1  receptor  of  fibronectin  and  the  vascular 
adhesion molecule –1 (VCAM-1), E-selectin and P-
selectin; b) the thrombospondin and/or collagen and 
receptor CD36, present on the surface of endothelial 
cells, platelets and reticulocyte-rich subpopulations 
of  normal  and  sickle  erythrocytes;  c)  the  sulfate 
glycolipids,  which  bind  thrombospondin,  von 
Willebrand factor multimer and laminin
2,42,43; d) the 
Lutheran blood group proteins (BCAM/LU), which 
expression  is  increased  in  red  cells  from  SCD 
patients  that  bind  to  5  subunit  of  laminin,  a 
component  of  extracellular  subendothelial 
matrix
44,45; e) the ICAM-4 (Landstein-Weiner blood 
group  glycoprotein- LW),  which  binds  V3 
integrin receptors on endothelial cells
46-49; and f) the 
exposure of phosphatydyl-serine (PS), detectable in 
a  subpopulation  of  sickle  red  cells,  which 
participates  in  sickle  cell  adhesion  to  activated 
endothelium
50-54 (Figure 2).  Ex vivo and in vitro
experimental  studies  have  shown  that 
thrombospondin- and  von  Willebrand  factor-
mediated  interaction  between  sickle  red  cells  and 
endothelium via  V3 integrin might be blocked 
by  monoclonal  antibodies  against  V3  integrin 
receptors
42,48,55.  Recent study  with  short  synthetic 
peptides  interfering  with  ICAM-4  and   V3 
integrin binding  have  been  evaluated  in  ex  vivo 
system, showing a reduction in  sickle erythrocyte 
adhesion to activated endothelial cells allowing to 
consider the blocking of this adhesion pathway as 
possible  therapeutic  new  strategy  in  treatment  of 
acute sickle cell events
48,55.
The  binding  between  thrombospondin,  von 
Willebrand  factor  and  laminin,  which  mediates 
sickle cell-endothelial adherence, might be blocked 
by anionic polysaccharides such as high molecular 
weight dextran sulfate or chondroitin sulfate
2,42, 43. 
An  additional  therapeutic  approach  to  block 
sickle cell adhesion to endothelial cells is heparin 
that  might  interfer  with  sickle  cell  adhesion  to 
endothelial cells through P-selectin
56-59 or binding to 
TSP  that  can  mediate  the  interactions  between 
sickle  erythrocytes  and  the  vascular  endothelial
surface.  A  double  blind  randomized  trial  with 
tinzaparin in SCD patients during acute VOCs has 
documented a reduction of severity and duration of 
the VOCs
51,60.
Molecules  modulating  inflammatory  pathways 
involved  in  sickle  cell-endothelial  adhesion:
Chronic inflammatory state has been described in 
SCD  patients  characterized  by  increase  plasma 
levels of acute phase proteins, of soluble cytokines 
such as IL1, IL6, TNF-  and endothelin-1 (ET-1) 
that are further elevated during acute VOCs. These 
factors  participate  to  leukocyte  chemotasis, 
modulate vascular tone and contribute in sickle cell 
related  tissue  damage.  Thus,  anti-inflammatory 
therapy  has  been  propose  to  interfere  with 
inflammatory  storm  and  abnormal  vascular 
activation
61.  Sulfasalazine  is  an  anti-inflammatory 
molecule and can inhibit the transcription of nuclear 
factor NF-kB and interferring with endothelial cell 
activation
62-65.  Transgenic  sickle  cell  mice  treated 
with  sulfasalazine  show  a  reduction  in  activated Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 2. Schematic diagram of possible therapeutic targets for agents that interfere with adherence of sickle red cells (RBC) or 
reticulocytes to  abnormally  activated  endothelial  cells. PS: phosphatidylserine; TSP:  thrombospondine;  Ab anti-band  3: natural 
occurring antibodies (NTAb) anti-band 3; vW: von Willebrand; BCAM/LU: Lutheran blood group protein; ICAM-4: Landstein-
Weiner (LW) blood group glycoprotein  (modified from De Franceschi L et al. Haematologica 89: 348, 2004). 
circulating  endothelial  cells,  and  in  VCAM-1, 
ICAM  and  E-selectin  vascular  wall  endothelial 
expression. In a pilot study, the  administration of 
sulfasalazine  to  sickle  cell  patients  results  in 
reduction  in  the  abnormal  endothelial  activation
4.  
Another  possible  strategy  aimed  at  reducing  the 
adhesion of sickle red cells to vascular endothelium 
is the inhibition of interactions between leukocytes 
already adherent to endothelium and sickle red cells 
during  vaso-occlusive  events
66.    Based  on  the  in 
vitro evidence  that  immunoglobulin  (Ig) 
significantly reduces the binding of sickle red cells 
to  neutrophils  in  transgenic  sickle  cell  mice,  the 
infusion  of  Ig  in  vivo  was  shown  to  inhibit  the 
interaction between sickle red cells and leukocytes 
in the cremasteric venules, suggesting that Ig may 
act  either  by  inhibitiing  the  interactions  between 
sickle red cells and leukocytes and/or by reducing 
the  number  of  adherent  leukocytes
66.  In  humans, 
three  out  of  four  sickle  cell  patients  treated  with 
infusion  of  Ig  showed  some  beneficial  effect, 
whereas in the fourth case the treatment accelerated 
a vaso-occlusive crisis
66,67. Since Ig infusion might 
be  related  to  severe  side  effects  such  as  renal 
toxicity  and  thrombosis,  it  should  be  used  with 
caution in sickle cell patients.
Recent studies have shown the important role of
ET-1 in acute sickle cell related VOCs in a  mouse 
model for SCD
68,69. The block of ET-1 actions was 
obtained directly by the ET-1 receptors antagonist, 
Bosentan,  evaluating  its  effects  on  SCD  mouse 
kidney  as  target  organ  and  indirectly  by  the 
inhibition of phosphodiesterase-4 with Rolipram in 
a  model  of  early  pulmonary  hypertension
68,69. 
Bosentan  is actually under evaluation in a phase III 
clinical  trial  in  SCD  patients  with  pulmonary 
hypertension
70. 
The possibility of delivering oxygen directly to 
sickled  red  cells  entrapped in  partially obstructed 
vessels  has  also  been  explored.  Perflubron-based 
fluorocarbon  emulsion  (PFE)  decreases  the 
peripheral  vascular  resistance  ex  vivo  in  the 
mesocaecal  vasculature  of  rats,  due  more  to  its 
ability  to  dissolve  oxygen  than  to  its  ability  to 
modify the vascular tone
71. 
Recently,  Hebbel  et  al  have  reported  the 
beneficial effects of histone deacetylase inhibitors 
on  vascular  pathology  in  mouse  model  for  sickle 
cell  disease
72.  The  Authors  observed  multiple 
therapeutic  effects  of  these  compounds  as:  (i) 
inducers of HbF; (ii) iron chelators; (iii) modulators 
of vascular damage and abnormal activation sickle 
cell related (i.e.: reduction of VCAM-1 expression). Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
The  heme-oxygenase-1  (HO-1)  connection: In 
different  sickle  cell  mouse  models  under  steady 
state,  Belcher  et  al  have  shown  up-regulation  of 
cytoprotective  gene  as  heme oxygenase-1  (HO-1) 
and  a  reduction  of  the  sickle  cell  related  organ 
damage when pathological mice were treated with 
heme oxygenase-1 products
63,73. In SCD patients in 
steady  state,  the  gene  expression  profiling  of 
circulating  leukocytes  has  shown  increased  HO-1 
and biliverdin reductase as well as in kidney and in 
circulating  endothelial  cells
74,75,  suggesting  an 
induction of cell protective systems in response to 
chronic  inflammatory  stress  characterizing  SCD. 
However, the still open question is whether these 
cytoprotective  systems  are  rapidly  and  further 
induced  driving  a  continuous  cellular  protection 
during acute sickle cell vaso-occlusive crisis. 
c)  Nitric  Oxide  (NO)  based  therapies  in  sickle 
cell  disease: Nitric  oxide  (NO)  is  a  potent 
vasodilator  and  inhibitor  of  vascular  remodeling 
and  also  affects  the  multi-step  cascade  of  events 
involved  in  leukocyte,  platelet  and  endothelial 
activation.  NO  is  generated  from  L-Arginine  by 
endothelial  cells  via  constitutive  (eNOS)  and 
inflammatory  inducible  nitric  oxide  synthases 
(iNOS). SCD is characterized by relative reduction 
in NO bioavaibility that contributes to endothelial 
abnormal  activation  and  SCD  organ  damage.  In 
addition chronic hemolysis leading to increase the 
plasma levels of hemoglobin that is an efficient NO 
buffer, contributes in reducing NO levels in SCD. 
Recent studies have focused on inhaled NO for 
the treatment of tissue damage in various ischaemic 
syndromes,  including  cardiovascular  disease, 
pulmonary  hypertension,  and  acute  lung  distress 
syndromes. The possible therapeutic role of inhaled 
NO has been studied in different animal models of 
lung  injury  induced  by  ischaemia/reperfusion. 
Inhaled  NO  prevents  leukocyte  migration  and 
reduces  the  permeability  of  the  peripheral 
microvasculature.  In  association  with  surfactant, 
inhaled NO alleviates alveolar edema and reduces 
bronchoalveolar  leukocyte  and  neutrophil 
infiltration  in  animal  models  of  ischaemic  lung 
injury.  A  placebo-controlled  randomized  clinical 
trial of inhaled NO in SCD has recently reported 
beneficial  results  in  the  treatment  of  acute  vaso-
occlusive crisis, although the mechanism of action 
remains  unknown.  Plasma  NO  metabolites  are 
decreased  in  SCD  patients  during  vaso-occlusive 
crisis associated with severe pain and also in acute 
chest  syndrome
32.  A  decrease  in  exhaled  NO  has 
been reported in  sickle cell patients, suggesting a 
role for NO in the pathogenesis of the pulmonary 
complications
76.   In a transgenic  mouse model of 
sickle cell disease, it has been shown that inhaled 
NO  provides  protection  during 
ischaemia/reperfusion  lung  injury,  in  which 
endothelial NO production is reduced
77,78. 
In  addition  NO-donor  as  polynitroxy-albumine 
and  nitroxic- albumine  have  been  shown  to  be 
effective in reducing inflammatory state in a SCD 
mouse strain and to reduce the hypoxia induce lung 
damage in another mouse model of acute VOCs
79,80.
Another  possible  therapeutic  strategy  for 
increased  NO  production  in  sickle  cell  disease  is 
supplementation of L-Arginine. Morris et al showed 
that L-Arginine supplementation alone induces an 
unexpected  decrease  in  NO  metabolite 
production
11,81.  In  a  subsequent  pilot  study,  an 
increase in NO metabolites was observed when L-
Arginine was co-administrated with HU, suggesting 
that  the  combination  treatment  may  have  a 
synergistic effect on NO production
2,31. A phase II 
trial  on  L-Arginine  supplementation  in  SCD  has 
shown no effects on NO levels and on erythrocyte 
features. 
d) Antioxidant agents in sickle cell disease: SCD 
is characterized by a pro-oxidant environment due 
to  high  production  of  reactive  oxygen  species 
(ROS)  related  to  increased  levels  of  free 
pathological iron and heme groups associated with a 
reduction in antioxidant systems such as GSH
82-85. 
Studies in vitro on SCD red cells have shown that 
iron chelation by deferipone (L1) reduce the sickle 
red cell membrane  susceptibility to iron mediated 
oxidative  damage
82,86.  In  vivo  study  on  SCD 
patients supplemented with L-glutamate to increase 
GSH  and  glutamate  levels  have  shown  some 
improvement of chronic pain
83.
Conclusions: In conclusion,  the  emerging  picture 
for  treatment  of  sickle  cell  disease  is  that 
abnormalities  ranging  from  membrane  cation
transport pathways to  red cell membrane  proteins 
structure  and  function,  or  red  cell-endothelial 
adhesive  events,  might  constitute  new 
pharmacological  targets  for  treating  sickle  cell 
disease.  Prospective  therapy  for  SCD  need  to 
combine molecules with different pharmacological 
targets in order to increase their therapeutic efficacy 
and  to  reduce  their  side  effects  (e.g.,  volume-
controlling  drugs  and  either  hydroxyurea  or  anti-
adhesive molecules).Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
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